TuHURA Biosciences, Inc. (HURA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-11-16. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 66/100 (HIGH), 1.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 17.43% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Evidence and freshness
Record counts and statuses were computed on 2026-11-17. A source date shows only when we store one; otherwise it says “not recorded”. Spot an error? Report a data error.
| PDUFA / FDA dates | 0 | No records No upcoming FDA decision date found in the company's SEC filings |
SEC 8-K filing |
| Clinical trials | 2 | Current Updated within the last 14 days |
ClinicalTrials.gov Registry queried: Nov 16, 2026 · ingested Nov 16, 2026 |
| Insider activity | 0 | Unavailable No record on file; source last refreshed Nov 17, 2026 |
SEC EDGAR Form 4 |
| Dilution risk | 1 | Derived Derived score calculated from SEC data, not a raw record |
DilutionWatch score (derived from SEC filings) source date not recorded · ingested Nov 17, 2026 |
| Short interest | 1 | Current Updated within the last 21 days |
FINRA short interest source date not recorded · ingested Nov 17, 2026 |
| Publications | 1 | Current Updated within the last 30 days |
PubMed source date not recorded · ingested Nov 16, 2026 |
How the signal grade is calculated
The score (0–100) is a weighted average of the source-backed signals we hold for a company: FDA decision date 35%, clinical trials 25%, insider buying 15%, dilution risk 8%, signal convergence 7%, short interest 3%, and 0.5–2% each for smaller signals. A signal we have no record for drops out and the others share its weight. Grades: A ≥ 80, B ≥ 65, C ≥ 50, D ≥ 35, F below 35.
What drives this company's 47.2/100 (grade D):
- Clinical trials: signal score 0.42, weight used 68%, 28.5 points
- Dilution risk: signal score 0.66, weight used 22%, 14.5 points
- Short interest: signal score 0.50, weight used 8%, 4.1 points
- Publications: signal score 0.05, weight used 1%, 0.1 points
Freshness: PDUFA dates that have passed score 0; clinical-trial records older than 90 days are ignored; dilution scores older than 7 days are withdrawn; scores are recalculated daily. Derived signals: the overall score and grade, the dilution-risk score (DilutionWatch, calculated from SEC filings) and signal convergence. The grade is not a forecast of FDA approval, a trial result or a stock move, and not investment advice.
Recent News & SEC Filings
- TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
- TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
- HURA: First Look at IFx-2.0 Deep-Seated Tumors
- TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
- TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
- TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
- TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
- TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- SIRT2-mediated deacetylation of LCK governs the magnitude of T cell receptor signaling. — Nat Immunol 2026 Feb PMID 41611868
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for TuHURA Biosciences, Inc..
Full HURA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.